Skip to main content
. 2018 Jan 30;9:94. doi: 10.3389/fimmu.2018.00094

Figure 4.

Figure 4

IL-6 signaling in LNCaP-JAK1 inducing proliferation arrest and antiviral state. (A) Cell proliferation analysis by methylene blue assay. LNCaP or LNCaP-JAK1 cells were incubated, or not, with IL-6 (5 ng/mL) for the indicated time points. Quantification was in Figure 3A. *p < 0.05. **p < 0.005. (B) Immunoblot analysis of NS3 expression upon treatment with IL-6. Indicated cells were treated, or not, with IL-6 (5 ng/mL, 14-h pretreatment and throughout infection), and infected (or not) with EHDV-TAU (moi = 0.5, 48 h). (C) Fold change in EHDV-TAU production following IL-6 treatment. LNCaP or LNCaP-JAK1 cells were pretreated (or not) with IL-6 (5 ng/mL, 14 h) and infected with EHDV-TAU in the absence or presence of IL-6. Titers were determined by plaque assay. Significance analysis as in A. (D) Immunoblot analysis of LNCaP cells treated, or not, with high concentrations of IL-6 (20 or 50 ng/mL), and infected (or not) with EHDV-TAU (moi = 0.5, 48 h).